46 related articles for article (PubMed ID: 38467131)
1. Activity of venetoclax in patients with relapsed or refractory chronic lymphocytic leukaemia: analysis of the VENICE-1 multicentre, open-label, single-arm, phase 3b trial.
Kater AP; Arslan Ö; Demirkan F; Herishanu Y; Ferhanoglu B; Diaz MG; Leber B; Montillo M; Panayiotidis P; Rossi D; Skarbnik A; Tempescul A; Turgut M; Mellink CH; van der Kevie-Kersemaekers AF; Lanham S; Sale B; Del Rio L; Popovic R; Chyla BJ; Busman T; Komlosi V; Wang X; Sail K; Pena GE; Vizkelety T; Forconi F
Lancet Oncol; 2024 Apr; 25(4):463-473. PubMed ID: 38467131
[TBL] [Abstract][Full Text] [Related]
2. Venetoclax for chronic lymphocytic leukaemia progressing after ibrutinib: an interim analysis of a multicentre, open-label, phase 2 trial.
Jones JA; Mato AR; Wierda WG; Davids MS; Choi M; Cheson BD; Furman RR; Lamanna N; Barr PM; Zhou L; Chyla B; Salem AH; Verdugo M; Humerickhouse RA; Potluri J; Coutre S; Woyach J; Byrd JC
Lancet Oncol; 2018 Jan; 19(1):65-75. PubMed ID: 29246803
[TBL] [Abstract][Full Text] [Related]
3. First-line venetoclax combinations versus chemoimmunotherapy in fit patients with chronic lymphocytic leukaemia (GAIA/CLL13): 4-year follow-up from a multicentre, open-label, randomised, phase 3 trial.
Fürstenau M; Kater AP; Robrecht S; von Tresckow J; Zhang C; Gregor M; Thornton P; Staber PB; Tadmor T; Lindström V; Juliusson G; Janssens A; Levin MD; da Cunha-Bang C; Schneider C; Goldschmidt N; Vandenberghe E; Rossi D; Benz R; Nösslinger T; Heintel D; Poulsen CB; Christiansen I; Frederiksen H; Enggaard L; Posthuma EFM; Issa DE; Visser HPJ; Bellido M; Kutsch N; Dürig J; Stehle A; Vöhringer M; Böttcher S; Schulte C; Simon F; Fink AM; Fischer K; Holmes EE; Kreuzer KA; Ritgen M; Brüggemann M; Tausch E; Stilgenbauer S; Hallek M; Niemann CU; Eichhorst B
Lancet Oncol; 2024 Jun; 25(6):744-759. PubMed ID: 38821083
[TBL] [Abstract][Full Text] [Related]
4. Low incidence of tumor lysis syndrome in elderly patients with chronic lymphocytic leukemia treated with venetoclax under real-world conditions: results from the prospective observational VeRVe study.
Schwaner I; Kuhn T; Losem C; Wolff T; Otremba B; Zaiss M; Hülsenbeck J; Famulla K; Nösslinger T; Rossi D
Ann Hematol; 2024 Jun; 103(6):2013-2020. PubMed ID: 38421404
[TBL] [Abstract][Full Text] [Related]
5. Zandelisib with continuous or intermittent dosing as monotherapy or in combination with rituximab in patients with relapsed or refractory B-cell malignancy: a multicentre, first-in-patient, dose-escalation and dose-expansion, phase 1b trial.
Pagel JM; Soumerai JD; Reddy N; Jagadeesh D; Stathis A; Asch A; Salman H; Kenkre VP; Iasonos A; Llorin-Sangalang J; Li J; Zelenetz AD
Lancet Oncol; 2022 Aug; 23(8):1021-1030. PubMed ID: 35835137
[TBL] [Abstract][Full Text] [Related]
6. A multicenter study of venetoclax-based treatment for patients with Richter transformation of chronic lymphocytic leukemia.
Hampel PJ; Swaminathan M; Rogers KA; Parry EM; Burger JA; Davids MS; Ding W; Ferrajoli A; Hyak JM; Jain N; Kenderian SS; Wang Y; Wierda WG; Woyach JA; Parikh SA; Thompson PA
Blood Adv; 2024 May; 8(10):2342-2350. PubMed ID: 38537065
[TBL] [Abstract][Full Text] [Related]
7. Real-world evidence of obinutuzumab and venetoclax in previously treated patients with chronic lymphocytic leukemia or small lymphocytic lymphoma.
Lei MM; Sorial MN; Lou U; Yu M; Medrano A; Ford J; Nemec RA; Abramson JS; Soumerai JD
Leuk Lymphoma; 2024 May; 65(5):653-659. PubMed ID: 38293753
[TBL] [Abstract][Full Text] [Related]
8. Venetoclax and Cobimetinib in Relapsed/Refractory AML: A Phase 1b Trial.
Konopleva MY; Dail M; Daver NG; Garcia JS; Jonas BA; Yee KWL; Kelly KR; Vey N; Assouline S; Roboz GJ; Paolini S; Pollyea DA; Tafuri A; Brandwein JM; Pigneux A; Powell BL; Fenaux P; Olin RL; Visani G; Martinelli G; Onishi M; Wang J; Huang W; Dunshee DR; Hamidi H; Ott MG; Hong WJ; Andreeff M
Clin Lymphoma Myeloma Leuk; 2024 Jun; 24(6):364-374. PubMed ID: 38378362
[TBL] [Abstract][Full Text] [Related]
9. Pirtobrutinib
Al-Sawaf O; Jen MH; Hess LM; Zhang J; Goebel B; Pagel JM; Abhyankar S; Davids MS; Eyre TA
Haematologica; 2024 Jun; 109(6):1866-1873. PubMed ID: 38031799
[TBL] [Abstract][Full Text] [Related]
10. An update on the efficacy of Venetoclax for chronic lymphocytic leukemia.
Lovell AR; Sawyers J; Bose P
Expert Opin Pharmacother; 2023; 24(11):1307-1316. PubMed ID: 37226798
[TBL] [Abstract][Full Text] [Related]
11. Management and use of healthcare resources in patients with chronic lymphocytic leukemia initiating venetoclax in routine clinical practice.
Banerji V; Aw A; Laferriere N; Abdel-Samad N; Peters A; Johnson NA; Bernard MP; Gopalakrishnan S; Bull SJ; Fournier PA; Klil-Drori AJ; Hay AE; Robinson S; Owen C
Leuk Lymphoma; 2024 May; 65(5):609-617. PubMed ID: 38235709
[TBL] [Abstract][Full Text] [Related]
12. Venetoclax for the treatment of multiple myeloma: Outcomes outside of clinical trials.
Sidiqi MH; Al Saleh AS; Kumar SK; Leung N; Jevremovic D; Muchtar E; Gonsalves WI; Kourelis TV; Warsame R; Buadi FK; Lacy MQ; Kyle RA; Go R; Hobbs M; Dispenzieri A; Dingli D; Hayman SR; Gertz MA; Rajkumar SV; Kapoor P
Am J Hematol; 2021 Sep; 96(9):1131-1136. PubMed ID: 34115387
[TBL] [Abstract][Full Text] [Related]
13. Case report: Successful treatment of refractory immune thrombocytopenia in chronic lymphocytic leukaemia with venetoclax monotherapy.
Woo T; Carter M; Follows G; Patten PE
Front Oncol; 2023; 13():1260003. PubMed ID: 37920161
[TBL] [Abstract][Full Text] [Related]
14. GAIA/CLL13 provides further insight on venetoclax use in chronic lymphocytic leukaemia.
Rogers KA
Lancet Oncol; 2024 Jun; 25(6):685-687. PubMed ID: 38821078
[No Abstract] [Full Text] [Related]
15. Fixed-Duration Pirtobrutinib plus Venetoclax with or without Rituximab in Relapsed/Refractory CLL: Phase 1b BRUIN Trial.
Roeker LE; Woyach JA; Cheah CYY; Coombs CC; Shah NN; Wierda WG; Patel MR; Lamanna N; Tsai DE; Nair BC; Wang C; Zhao X; Liu D; Radtke D; Chapman S; Marella N; McNeely SC; Brown JR
Blood; 2024 Jun; ():. PubMed ID: 38861666
[TBL] [Abstract][Full Text] [Related]
16. Real-World Treatment Patterns and Outcomes by Line of Therapy and Race in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Treated in the United States: Results From the Final Analysis of the Prospective, Observational, informCLL Registry.
Ghosh N; Sharman JP; Gutierrez M; Khan W; Qureshi ZP; Raz A; Girardi V; Krigsfeld GS; Barrientos JC
Clin Lymphoma Myeloma Leuk; 2024 May; ():. PubMed ID: 38845276
[TBL] [Abstract][Full Text] [Related]
17. Safety of extended pirtobrutinib exposure in relapsed and/or refractory B-cell malignancies.
Roeker LE; Coombs CC; Shah NN; Jurczak W; Woyach JA; Cheah CY; Patel K; Maddocks K; Wang Y; Zinzani PL; Munir T; Koh Y; Thompson MC; Muehlenbein CE; Wang C; Sizelove R; Abhyankar S; Hasanabba S; Tsai DE; Eyre TA; Wang M
Acta Haematol; 2024 Jun; ():. PubMed ID: 38824917
[TBL] [Abstract][Full Text] [Related]
18. Combination fedratinib and venetoclax has activity against human B-ALL with high FLT3 expression.
Rinella SP; Bell HC; Hess NJ; Hoang NM; Nguyen TT; Turicek DP; Shi L; Rui L; LaBelle JL; Capitini CM
bioRxiv; 2024 May; ():. PubMed ID: 37333339
[TBL] [Abstract][Full Text] [Related]
19. Erratum: Real-World Health Care Resource Use and Costs Among Patients With Chronic Lymphocytic Leukemia Treated With Venetoclax-Based and Bruton Tyrosine Kinase Inhibitor-Based Regimens in the Second-Line Setting.
JCO Oncol Pract; 2024 Jun; ():OP2400351. PubMed ID: 38848514
[No Abstract] [Full Text] [Related]
20. Chronic lymphocytic leukaemia in pregnancy: a case report and literature review.
Maxwell C; Grady R; Crump M
Obstet Med; 2009 Dec; 2(4):168-9. PubMed ID: 27579065
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
